Skip to main content
Premium Trial:

Request an Annual Quote

Lucence, NovogeneAIT Genomics Singapore Ink Precision Cancer Medicine Alliance

NEW YORK (GenomeWeb) — Singapore-based Lucence Diagnostics and NovogeneAIT Genomics Singapore announced today that they have partnered to develop next-generation sequencing-based tests for precision cancer treatment for the Asian market.

According to the partners, the tests will be designed to analyze the genetics of cancer tissue to help personalize a patient's treatment regimen and will focus on cancers prevalent in Asia. Additional terms of the deal were not disclosed.

"This partnership combines NovogeneAIT's high-quality tissue sequencing capabilities with our analytics and insights on Asian cancer targets and treatments," Lucence Founder and CEO Min-Han Tan said in a statement. "This means deeper and more meaningful interpretation for complex cancer genetics testing."

Late last year, Lucence partnered with AstraZeneca to improve access to BRCA testing for women in Singapore with ovarian cancer.

NovogeneAIT Genomics Singapore is a joint venture between Novogene and AITbiotech that operates a high-throughput NGS center in Singapore.

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.